Bloodlines Series: CAR T-cell Therapy Shows Promise for Smoldering Myeloma
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
Category: Bloodlines
In the CAR-PRISM clinical trial, the CAR T-cell therapy ciltacabtagene autoleucel showed promise for treating high-risk smoldering myeloma.
Learn about smoldering myeloma and the first treatment approved by the U.S. Food and Drug Administration to prevent its...
A single-cell atlas helped clarify diverse forms of acute myeloid leukemia, with potential implications for improving diagnostic, prognostic, and...
Multiple myeloma can be tricky to treat, but many treatment options exist, and new research is constantly supporting more.